Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study
- PMID: 32278005
- PMCID: PMC7141624
- DOI: 10.1016/j.jhep.2020.03.044
Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study
Conflict of interest statement
Conflicts of interest The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.
Comment in
-
NAFLD or comorbidities, that is the question.J Hepatol. 2020 Sep;73(3):723. doi: 10.1016/j.jhep.2020.04.026. Epub 2020 Apr 22. J Hepatol. 2020. PMID: 32333924 Free PMC article. No abstract available.
-
Younger patients with MAFLD are at increased risk of severe COVID-19 illness: A multicenter preliminary analysis.J Hepatol. 2020 Sep;73(3):719-721. doi: 10.1016/j.jhep.2020.04.027. Epub 2020 Apr 26. J Hepatol. 2020. PMID: 32348790 Free PMC article. No abstract available.
-
No evidence for an increased liver uptake of SARS-CoV-2 in metabolic-associated fatty liver disease.J Hepatol. 2020 Sep;73(3):717-718. doi: 10.1016/j.jhep.2020.04.035. Epub 2020 Apr 30. J Hepatol. 2020. PMID: 32360995 Free PMC article. No abstract available.
-
Reply to: 'NAFLD or comorbidities, that is the question'.J Hepatol. 2020 Sep;73(3):724-725. doi: 10.1016/j.jhep.2020.05.006. Epub 2020 May 12. J Hepatol. 2020. PMID: 32407814 Free PMC article. No abstract available.
-
Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores.Gut. 2020 Aug;69(8):1545-1547. doi: 10.1136/gutjnl-2020-321611. Epub 2020 May 15. Gut. 2020. PMID: 32414813 No abstract available.
-
Lack of genetic evidence that fatty liver disease predisposes to COVID-19.J Hepatol. 2020 Sep;73(3):709-711. doi: 10.1016/j.jhep.2020.05.015. Epub 2020 May 20. J Hepatol. 2020. PMID: 32445883 Free PMC article. No abstract available.
-
Is the increased risk for MAFLD patients to develop severe COVID-19 linked to perturbation of the gut-liver axis?J Hepatol. 2021 Feb;74(2):487-488. doi: 10.1016/j.jhep.2020.05.051. Epub 2020 Jun 20. J Hepatol. 2021. PMID: 32574578 Free PMC article. No abstract available.
-
Inflammasome activation and pyroptosis in lymphopenic liver patients with COVID-19.J Hepatol. 2020 Nov;73(5):1258-1262. doi: 10.1016/j.jhep.2020.06.034. Epub 2020 Jul 6. J Hepatol. 2020. PMID: 32645361 Free PMC article. No abstract available.
-
Obese patients with NASH have increased hepatic expression of SARS-CoV-2 critical entry points.J Hepatol. 2021 Feb;74(2):469-471. doi: 10.1016/j.jhep.2020.09.027. Epub 2020 Oct 20. J Hepatol. 2021. PMID: 33096086 Free PMC article. No abstract available.
-
NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression - The debate continues.J Hepatol. 2021 Feb;74(2):482-484. doi: 10.1016/j.jhep.2020.09.006. Epub 2020 Nov 19. J Hepatol. 2021. PMID: 33223215 Free PMC article. No abstract available.
-
Assessing causal relationships between COVID-19 and non-alcoholic fatty liver disease.J Hepatol. 2022 Mar;76(3):740-742. doi: 10.1016/j.jhep.2021.11.014. Epub 2021 Nov 20. J Hepatol. 2022. PMID: 34813919 Free PMC article. No abstract available.
References
-
- Chinese Clinical Guidance for COVID-19 Pheumonia Diagnosis and Treatment. http://kjfy.meetingchina.org/msite/news/show/cn/3337.html
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical